3 of Wall Street’s Favorite Stocks with Questionable Fundamentals

Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional pressures that can sometimes lead to overly optimistic forecasts.

Unlike the investment banks, we created StockStory to provide independent analysis that helps you determine which companies are truly worth following. That said, here are three stocks where Wall Street may be overlooking some important risks and some alternatives with better fundamentals.

ACV Auctions (ACVA)

Consensus Price Target: $9.34 (42.5% implied return)

Founded in 2014, ACV Auctions (NYSE:ACVA) is an online auction marketplace for car dealers and wholesalers to buy and sell used cars.

Why Are We Wary of ACVA?

1. High servicing costs result in an inferior gross margin of 27.3% that must be offset through higher volumes
2. Highly competitive market means it’s on the never-ending treadmill of sales and marketing spend

ACV Auctions is trading at $6.56 per share, or 12.2x forward EV/EBITDA. To fully understand why you should be careful with ACVA, check out our full research report (it’s free).

Shake Shack (SHAK)

Consensus Price Target: $96.17 (54.4% implied return)

Started as a hot dog cart in New York City's Madison Square Park, Shake Shack (NYSE:SHAK) is a fast-food restaurant known for its burgers and milkshakes.

Why Do We Think Twice About SHAK?

1. Operating margin of 2.3% falls short of the industry average, and the smaller profit dollars make it harder to react to unexpected market developments
2. Low free cash flow margin of 2% for the last two years gives it little breathing room, constraining its ability to self-fund growth or return capital to shareholders
3. ROIC of -0.3% reflects management’s challenges in identifying attractive investment opportunities

At $62.26 per share, Shake Shack trades at 48.2x forward P/E. Read our free research report to see why you should think twice about including SHAK in your portfolio.

Bio-Techne (TECH)

Consensus Price Target: $61.42 (21.5% implied return)

With a catalog of hundreds of thousands of specialized biological products used in laboratories worldwide, Bio-Techne (NASDAQ:TECH) develops and manufactures specialized reagents, instruments, and services that help researchers study biological processes and enable diagnostic testing and cell therapy development.

Why Should You Sell TECH?

1. Absence of organic revenue growth over the past two years suggests it may have to lean into acquisitions to drive its expansion
2. Modest revenue base of $1.21 billion gives it less fixed cost leverage and fewer distribution channels than larger companies
3. Eroding returns on capital from an already low base indicate that management’s recent investments are destroying value

Bio-Techne’s stock price of $50.55 implies a valuation ratio of 25.8x forward P/E. Check out our free in-depth research report to learn more about why TECH doesn’t pass our bar.

Stocks We Like More

ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI is taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies.

Our AI system flagged Palantir before it ran 1,662%. AppLovin before it ran 753%. Nvidia before it ran 1,178%. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE.

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today.